Bristol Myers (BMY) Stock: Here’s What You Need To Know

Bristol Myers (NYSE:BMY) On August 5, 2016 Bristol Myers had a very rough day with respect to one of its targets in the pipeline. ┬áThe company’s PD-1 immune checkpoint inhibitor, known as Opdivo, failed to meet the primary endpoint of a phase 3 clinical trial. Bristol Myer’s stock did not have a good day after … Read more

Biotech Stock News (RXII) (MRK) (BMY) (CNAT) (ICPT)

Rxi Pharmaceuticals Corp (NASDAQ: RXII) Rxi Pharmaceuticals last week on March 23, 2015 presented at the 73rd Annual Academy of Dermatology in which the company reported ┬ápositive progress on clinical trial updates for its dermatology programs. The clinical trial with RXI-109-1301 phase 2a enrolled patients to be tested for hypertrophic scars on the abdomen only. … Read more